GEHC Stock Chart & Stats
$1100.00
$0.61(0.06%)
At close: 4:00 PM EDT
$1100.00
$0.61(0.06%)
Day’s Range― - ―
52-Week Range$1,020.11 - $1,709.97
Previous CloseN/A
Volume0.00
Average Volume (3M)143.00
Market Cap
$532.98B
Enterprise Value$37.74K
Total Cash (Recent Filing)$2.10B
Total Debt (Recent Filing)$10.09B
Price to Earnings (P/E)19.5
Beta0.55
Next Earnings
Nov 04, 2026EPS Estimate
20.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.48
Shares Outstanding451,686,250
10 Day Avg. Volume15
30 Day Avg. Volume143
Financial Highlights & Ratios
PEG Ratio4.14
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,364.07Price Target Upside24.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)85.37
Revenue Forecast (FY)$377.07B
Bulls Say, Bears Say
Bulls Say
Record Orders And BacklogSustained order momentum and a large, growing backlog provide durable demand visibility for equipment placements. That supports multi‑period revenue recognition, future service and consumable annuities, and smoother capital allocation, improving medium‑term revenue and cash flow predictability.
Recurring Services & Consumables GrowthServices and consumables growth strengthens recurring revenue mix and typically offers higher gross margins and stable cash conversion. A growing installed base monetized via service contracts and consumables underpins margin resilience and long‑term cash generation even if equipment cycles fluctuate.
PDx Strength And New Product RampHigh‑margin pharmaceutical diagnostics outperformance and early Flyrcado adoption diversify revenue into attractive, recurring, higher‑margin adjacencies. Successful new product commercialization and AI/diagnostic adoption can sustainably lift company margins and expand addressable market over years.
Bears Say
Patient Care Solutions WeaknessA material, loss‑making PCS segment creates persistent drag on consolidated profitability and ties up management attention. The ongoing strategic review signals potential divestiture or restructuring; either path carries execution risk, potential one‑time costs, and uncertain timing for margin recovery.
Free Cash Flow Decline & VolatilityA sharp TTM decline in free cash flow and one‑off refund distortions reduce near‑term financial flexibility for buybacks, investment, or debt paydown. Lower FCF conversion raises reliance on operating improvement to fund medium‑term targets and weakens cushion against cycles or large strategic moves.
Inflation & China HeadwindsSustained component and freight inflation compresses margins unless fully offset by pricing or cost actions. Concurrent China market softness reduces growth in a large market, limiting geographic diversification benefits and prolonging margin recovery, especially in price‑sensitive product lines.
GE Healthcare Technologies Inc News
GEHC FAQ
What was Ge Healthcare Technologies Inc.’s price range in the past 12 months?
Ge Healthcare Technologies Inc. lowest stock price was $1020.11 and its highest was $1709.97 in the past 12 months.
What is Ge Healthcare Technologies Inc.’s market cap?
Ge Healthcare Technologies Inc.’s market cap is $532.98B.
When is Ge Healthcare Technologies Inc.’s upcoming earnings report date?
Ge Healthcare Technologies Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 94 days.
How were Ge Healthcare Technologies Inc.’s earnings last quarter?
Ge Healthcare Technologies Inc. released its earnings results on Jul 29, 2026. The company reported $19.607 earnings per share for the quarter, beating the consensus estimate of $17.976 by $1.631.
Is Ge Healthcare Technologies Inc. overvalued?
According to Wall Street analysts Ge Healthcare Technologies Inc.’s price is currently Undervalued.
Does Ge Healthcare Technologies Inc. pay dividends?
Ge Healthcare Technologies Inc. does not currently pay dividends.
What is Ge Healthcare Technologies Inc.’s EPS estimate?
Ge Healthcare Technologies Inc.’s EPS estimate is 20.89.
How many shares outstanding does Ge Healthcare Technologies Inc. have?
Ge Healthcare Technologies Inc. has 451,686,250 shares outstanding.
What happened to Ge Healthcare Technologies Inc.’s price movement after its last earnings report?
Ge Healthcare Technologies Inc. reported an EPS of $19.607 in its last earnings report, beating expectations of $17.976. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Ge Healthcare Technologies Inc.?
Currently, no hedge funds are holding shares in MX:GEHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GE Healthcare Technologies Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,364.07 (24.01% Upside)
$1,364.07 (24.01% Upside)
Blogger Sentiment
Bullish
MX:GEHC Sentiment 86%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $112.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.90%
12-Months-Change
Fundamentals
Return on Equity
0.22%
Trailing 12-Months
Asset Growth
10.54%
Trailing 12-Months
Company Description
Ge Healthcare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
GEHC Company Deck
GEHC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed strong commercial momentum: record orders, backlog, solid revenue growth, PDx outperformance, AIS margin expansion, and progress on new AI-enabled products and Flyrcado ramp. Offsetting these positives were meaningful near-term challenges in Patient Care Solutions (13.5% organic decline and negative segment EBIT), inflationary headwinds (memory, oil, freight), and cash volatility driven by tariff refunds. Management maintained full-year guidance and reiterated medium-term targets, expressing confidence in recovery actions and the innovation pipeline.View all MX:GEHC earnings summariesGEHC Revenue Breakdown
44.82% Imaging
25.96% AVS
14.96% PCS
14.06% PDx
0.19% Other
GEHC Stock 12 Month Forecast
Average Price Target
$1,364.07
▲(24.01% Upside)